<DOC>
	<DOC>NCT01144286</DOC>
	<brief_summary>In order to find an optimal dose of arasertaconazole nitrate in the treatment of vulvovaginal candidiasis, a multicenter, randomized, double-blind, parallel, placebo-controlled study will be conducted to compare the therapeutic efficacy, safety and tolerability of three different doses of arasertaconazole nitrate (150 mg, 300 mg or 600 mg, pessaries).</brief_summary>
	<brief_title>Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Vulvovaginal</mesh_term>
	<criteria>Women aged between 18 to 65 years of age who have signed the informed consent. Not pregnant, not nursing. No indication of other vulvovaginitis or genital infections Positive 10% potassium hydroxide (KOH) preparation for budding yeast and/or pseudohyphae. Negative wet mount results for T. vaginalis and clue cells. Subjects with another vaginal or vulvar condition that would confound the interpretation of clinical response. Hypersensitivity to imidazole products administered topically. Any other medical condition which in the opinion of the investigator could interfere with study conduct.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>VVC</keyword>
	<keyword>candidiasis</keyword>
	<keyword>vaginal candidiasis</keyword>
</DOC>